Overview

The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:

Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
0
Participant gender:
Female
Summary
the study aims to evaluate the efficacy of intramyometrial Terlipressin injection versus intramyometrial Carbetocin injection on hemoglobin level in women undergoing abdominal myomectomy. Moreover, to evaluate their efficacy in decreasing blood loss on operative time and to describe the injection sequelae for the same population. This clinical study will be conducted in compliance with the clinical study protocol and applicable regulatory requirements.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wael Elbanna Clinic
Treatments:
Terlipressin
Criteria
Inclusion Criteria:

1. Women aged 16-45 years

2. Appropriate medical status for open surgery (Largest Myoma size from 4 cm up to 20 cm)

3. Baseline hemoglobin ≥9 g/dl

4. No contra-indications to the use of glyopressin or carbitocin

5. Myoma-related symptoms, such as pelvic pressure or pain, menorrhagia, or infertility

6. Not pregnant at the time of presentation

Exclusion Criteria:

1. Previous myomectomy

2. History of bleeding disorders

3. Concurrent anticoagulation therapy

4. History of Uncontrolled ischaemic heart disease

5. Any pelvic abnormalities requiring concomitant surgery

6. Treatment with a GnRH agonist or ulipristal acetate within three months preceding
surgery

7. Inability to understand and provide written informed consent.